Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?

摘要: Despite advances in the treatment of colorectal cancer (CRC), it remains second most common cause cancer-related death Western world. Angiogenesis is a complex process that involves formation new blood vessels from preexisting vessels. It essential for promoting survival, growth, and dissemination. The inhibition angiogenesis has been shown to prevent tumor progression experimentally, several chemotherapeutic targets have identified. These include anti-vascular endothelial growth factor (VEGF) treatments, such as bevacizumab (a VEGF-specific binding antibody) anti-VEGF receptor tyrosine kinase inhibitors, although antiangiogenic therapy be effective cancers, including CRC. However, also associated with its own side effects financial costs. Therefore, identification biomarkers are able identify patients who more likely benefit very important. This article intends concise summary potential can predict or prognosticate treatments CRC, what we expect near future.